Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus ALDORIL 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus ALDORIL 25.
ALDORIL 15 vs ALDORIL 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination